Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United ...

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in ...

Making it in the UFC demands more than skill — it demands grit, toughness, and a willingness to sacrifice. Fighters spend years pushing their bodies to the limit, often battling injuries and setbacks ...

Vincerx Pharma, Inc. (VINC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

The average one-year price target for Vincerx Pharma (NASDAQ:VINC) has been revised to 7.14 / share. This is an increase of 10.53% from the prior estimate of 6.46 dated October 31, 2023. The price ...

Vincerx Pharma Inc (NASDAQ:VINC) shares are trading lower by 9.7% to $0.81 during Friday’s session after the company priced an underwritten public offering, including 6 million shares of common stock ...

In a turbulent market environment, Vincerx Pharma, Inc. (VINC) stock has reached its 52-week low, trading at $1.3. According to InvestingPro analysis, the company maintains a healthy current ratio of ...

As of February 12, 2023, the average one-year price target for Vincera Pharma is $8.77. The forecasts range from a low of $3.03 to a high of $21.00. The average price target represents an increase of ...

ORWIGSBURG — Add another shiny medal to young Sam Vinc’s impressive collection — this one gold. The Tamaqua freshman finished with a 2-over-par 74 to take top honors at the Schuylkill League Golf ...